Citations

Clear

9383 citation(s) found for "Thomas, PS".

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
Berenson, Charles S., Lashner, Bret A., Korman, Louis Y. , Hohmann, Elizabeth , Louie, Thomas , Sims, Matthew , Pardi, Darrell S. , Kraft, Colleen S., Wang, Elaine E. L., Cohen, Stuart H. , Oneto, Caterina , Misra, Bharat , Pullman, John, Hasson, Brooke , McGovern, Barbara , Moltke, Lisa Von, Lee, Christine H. , Pardi, Darrell, McGovern, Barbara H , Deshpande, Abhishek , Kraft, Colleen S. , Feuerstadt, Paul , De, Ananya, Memisoglu, Asli, Lombardi, David A

Mayo Clinic

Clinical Infectious Diseases | August 3, 2023 | Volume: 77 | Issue: 11 | Pages: 1504-1510

10.1093/cid/ciad448 | PMID 37539715 Get It

Abstract Background Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind, placebo-controlled, randomized trial (ECOSPOR III), fecal microbiota spores, live (VOWST, Seres Therapeutics; hereafter “VOS,” formerly SER-109), an oral microbiota therapeutic, significantly reduced the risk of rCDI at week 8. We evaluated the efficacy of VOS compared with placebo in patients with comorbidities and other risk factors for rCDI. Methods Adults with rCDI were randomized to receive VOS or placebo (4 capsules daily for 3 days) following standard-of-care antibiotics. In this post hoc analysis, the rate of rCDI through week 8 was assessed in VOS-treated participants compared with placebo for subgroups including (i) Charlson comorbidity index (CCI) score category (0, 1–2, 3–4, ≥5); (ii) baseline creatinine clearance (<30, 30–50, >50 to 80, or >80 mL/minute); (iii) number of CDI episodes, inclusive of the qualifying episode (3 and ≥4); (iv) exposure to non-CDI-targeted antibiotics after dosing; and (v) acid-suppressing medication use at baseline. Results Of 281 participants screened, 182 were randomized (59.9% female; mean age, 65.5 years). Comorbidities were common with a mean overall baseline age-adjusted CCI score of 4.1 (4.1 in the VOS arm and 4.2 in the placebo arm). Across all subgroups analyzed, VOS-treated participants had a lower relative risk of recurrence compared with placebo. Conclusions In this post hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications, or comorbidities.
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Huamán, Moisés A. , Patel, Bela , Marshall, Christi E., Yarava, Anusha , Heath, Sonya L. , Fukuta, Yuriko , Blair, Janis E. , Spivak, Emily S , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Ram, Malathi , Das, Piyali, Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Laeyendecker, Oliver , Ehrhardt, Stephan , Lau, Bryan , Baksh, Sheriza , Shade, David , Ou, Jiangda , Gniadek, Thomas J. , Ziman, Alyssa , Bloch, Evan M. , Gerber, Jonathan M. , Ziman, Alyssa , Bloch, Evan M , Tobian, Aaron A R , Sullivan, David J , Huaman, Moises A , Laeyendecker, Oliver , Raval, Jay S. , Paxton, James H , Mosnaim, Giselle S , Anjan, Shweta , Meisenberg, Barry R. , Levine, Adam C , Shenoy, Aarthi , Currier, Judith S. , Broderick, Patrick B., Sutcliffe, Catherine G , Zand, Martin S. , Kassaye, Seble , Wang, Ying , Ford, Daniel E , Pekosz, Andrew , Klein, Sabra L , Casadevall, Arturo , Hanley, Daniel F. , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Sullivan, David

Mayo Clinic

Transfusion | August 3, 2023 | Volume: 63 | Issue: 9 | Pages: 1639-1648

10.1111/trf.17485 | PMID 37534607 Get It

AbstractBackgroundCOVID‐19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials.Study Design and MethodsWe analyzed data pertaining to transfusion‐related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders.ResultsThe combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic‐type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients' underlying disease, COVID‐19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43–1.31). Risk of urticaria and/or pruritus increased with a pre‐existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16–4.67). We did not observe any CCP‐attributed antibody disease enhancement in participants with COVID‐19 or increased risk of infection. There were no life‐threatening severe transfusion reactions and no patients required hospitalization related to transfusion‐associated complications.DiscussionOutpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID‐19.
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Weiss, Aaron R. , Scharschmidt, Thomas J. , Xue, Wei , Gao, Zhengya, Black, Jennifer O. , Choy, Edwin , Fanburg–Smith, Julie C. , Kao, Simon C. , Kayton, Mark L. , Kessel, Sandy, Lim, Ruth , Million, Lynn , Okuno, Scott H. , Ostrenga, Andrew , Parisi, Marguerite T. , Pryma, Daniel A. , Rosen, Mark, Terezakis, Stephanie , Venkatramani, Rajkumar , Zambrano, Eduardo , Wang, Dian , Hawkins, Douglas S. , Black, Jennifer O , Choy, Edwin , Kao, Simon C , Kayton, Mark L , Lim, Ruth , Million, Lynn , Okuno, Scott , Ostrenga, Andrew , Pryma, Daniel A , Randall, Robert Lor , Shulkin, Barry L , Terezakis, Stephanie A , Venkatramani, Rajkumar , Wang, Dian , Hawkins, Douglas S , Spunt, Sheri L , Weiss, Aaron R , Chen, Yen‐Lin , Davis, Jessica L. , Randall, R. Lor , Shulkin, Barry L. , Spunt, Sheri L.

Mayo Clinic

Journal of Clinical Oncology | July 31, 2023 | Volume: 41 | Issue: 31 | Pages: 4842-4848

10.1200/jco.23.00045 | PMID 37523624 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867 ). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B ( P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B ( P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.
Machine Learning-Based Prediction of in-Hospital Death for Patients with Takotsubo Syndrome: The InterTAK-ML Model
Filippo, Ovidio De , Cammann, Victoria L. , Vece, Davide Di , Schweiger, Victor , Niederseer, David , Szawan, Konrad A. , Würdinger, Michael , Koleva, Iva, Bellino, Michele , Vecchione, Carmine , Bossone, Eduardo , Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Jansen, Thomas , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Cuculi, Florim , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Akın, İbrahim , Poledníková, Karolína, Winchester, David E. , Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio, Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Liu, Kan , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Bruno, Francesco , Kong, William , Dalakoti, Mayank , Imori, Yoichi , Münzel, Thomas , Crea, Filippo , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Bossone, Eduardo , Vecchione, Carmine , Bruno, Francesco , von Lewinski, Dirk , Tschöpe, Carsten , Meyer, Philippe , Bilato, Claudio , Pancotti, Corrado , Silverio, Angelo , Dusi, Veronica , Parodi, Guido , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Himi, Toshiharu, Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T. , Ferrari, Gaetano Maria De , Fariselli, Piero , Citro, Rodolfo , D’Ascenzo, Fabrizio

Mayo Clinic

European Journal of Heart Failure | July 31, 2023 | Volume: 25 | Issue: 12 | Pages: 2299-2311

10.1002/ejhf.2983 | PMID 37522520 Get It

ABSTRACT Aims Takotsubo syndrome (TTS) is associated with a substantial rate of adverse events. We sought to design a machine learning (ML)-based model to predict the risk of in-hospital death and to perform a clustering of TTS patients to identify different risk profiles. Methods and results A ridge logistic regression-based ML model for predicting in-hospital death was developed on 3482 TTS patients from the International Takotsubo (InterTAK) Registry, randomly split in a train and an internal validation cohort (75% and 25% of the sample size, respectively) and evaluated in an external validation cohort (1037 patients). Thirty-one clinically relevant variables were included in the prediction model. Model performance represented the primary endpoint and was assessed according to area under the curve (AUC), sensitivity and specificity. As secondary endpoint, a K-medoids clustering algorithm was designed to stratify patients into phenotypic groups based on the 10 most relevant features emerging from the main model. The overall incidence of in-hospital death was 5.2%. The InterTAK-ML model showed an AUC of 0.89 (0.85–0.92), a sensitivity of 0.85 (0.78–0.95) and a specificity of 0.76 (0.74–0.79) in the internal validation cohort and an AUC of 0.82 (0.73–0.91), a sensitivity of 0.74 (0.61–0.87) and a specificity of 0.79 (0.77–0.81) in the external cohort for in-hospital death prediction. By exploiting the 10 variables showing the highest feature importance, TTS patients were clustered into six groups associated with different risks of in-hospital death (28.8% vs. 15.5% vs. 5.4% vs. 1.0.8% vs. 0.5%) which were consistent also in the external cohort. Conclusion A ML-based approach for the identification of TTS patients at risk of adverse short-term prognosis is feasible and effective. The InterTAK-ML model showed unprecedented discriminative capability for the prediction of in-hospital death.
Advancing specificity in delirium: The delirium subtyping initiative
Bowman, Emily M L , Fiest, Kirsten M. , Girard, Timothy D. , Jackson, Thomas , LaHue, Sara C. , MacLullich, Alasdair M. J. , McAuley, Daniel F. , Potter, Kelly , Sinha, Pratik , Slooter, Arjen J. C. , Sweeney, Aoife , Tieges, Zoë , Dellen, Edwin van , Wilcox, M. Elizabeth , Cunningham, Emma , Lindroth, Heidi L., Girard, Timothy D , MacLullich, Alasdair M J , Slooter, Arjen J C , Brummel, Nathan E. , Caplan, Gideon A. , Cunningham, Colm M. , Evered, Lisbeth Anne , Lindroth, Heidi , Oh, Esther S , Oldham, Mark , Page, Valérie , Pandharipande, Pratik , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | July 31, 2023 | Volume: 20 | Issue: 1 | Pages: 183-194

10.1002/alz.13419 | PMID 37522255 Get It

AbstractBACKGROUNDDelirium, a common syndrome with heterogeneous etiologies and clinical presentations, is associated with poor long‐term outcomes. Recording and analyzing all delirium equally could be hindering the field's understanding of pathophysiology and identification of targeted treatments. Current delirium subtyping methods reflect clinically evident features but likely do not account for underlying biology.METHODSThe Delirium Subtyping Initiative (DSI) held three sessions with an international panel of 25 experts.RESULTSMeeting participants suggest further characterization of delirium features to complement the existing Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision diagnostic criteria. These should span the range of delirium‐spectrum syndromes and be measured consistently across studies. Clinical features should be recorded in conjunction with biospecimen collection, where feasible, in a standardized way, to determine temporal associations of biology coincident with clinical fluctuations.DISCUSSIONThe DSI made recommendations spanning the breadth of delirium research including clinical features, study planning, data collection, and data analysis for characterization of candidate delirium subtypes.Highlights Delirium features must be clearly defined, standardized, and operationalized. Large datasets incorporating both clinical and biomarker variables should be analyzed together. Delirium screening should incorporate communication and reasoning.
O-065 Multicenter investigation into presentation, management and outcome of infectious intracranial aneurysms
Saad, Hassan , Newman, Sarah, Grossberg, Jonathan A , Cawley, C. Michael , Fox, C, Perez-Vaga, C, Burkhardt, Jan‐Karl , Salem, Mohamed M , Jabbour, Pascal , Starke, R, Lu, Victor M. , Levitt, M, Spiotta, Alejandro M , Alawieh, Ali , Dimisko, Laurie , Zohdy, Youssef M. , Pradilla, Gustavo , Jabbour, Pascal , Naamani, Kareem El , Schmidt, Richard F. , Gooch, Michael Reid , Abdelsalam, Ahmed , Levitt, M, Hertzberg, Vicki , Barrow, Daniel L. , Howard, Brian M

Mayo Clinic

SNIS 20th annual meeting oral abstracts | July 30, 2023 | Volume: No volume available | Issue: No issue available | Pages: A51.1-A51

10.1136/jnis-2023-snis.65 Get It

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
Turkel, Catherine C., Aurora, Sheena K. , Diener, Hans‐Christoph, Silberstein, Stephen D., Brin, Mitchell F. , Diener, Hans‐Christoph, Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Medicine | July 27, 2023 | Volume: 102 | Issue: S1 | Pages: e32600

10.1097/md.0000000000032600 | PMID 37499085 Get It

Chronic migraine (CM) is a neurological disease characterized by frequent migraine attacks that prevent affected individuals from performing daily activities of living, significantly diminish quality of life, and increase familial burden. Before onabotulinumtoxinA was approved for CM, there were few treatment options for these seriously disabled patients and none had regulatory approval. The terminology and recognition of CM evolved in parallel with the onabotulinumtoxinA clinical development program. Because there were no globally accepted classification criteria for CM when onabotulinumtoxinA was in development, the patient populations for the trials conducted by Allergan were determined by the Allergan migraine team in collaboration with headache scientists and clinicians. These trials and collaborations ultimately led to improvements in CM classifications. In 2010, onabotulinumtoxinA became the first medication and first biologic approved specifically to prevent headaches in patients with CM. Approval was based on 2 similarly designed phase 3, double-blind, randomized, placebo-controlled, multicenter clinical studies. Both studies showed significantly greater improvements in mean change from baseline in headache-day frequency in patients with CM receiving onabotulinumtoxinA compared with those receiving placebo. The safety and effectiveness of onabotulinumtoxinA have been established globally in >5000 patients with CM with or without medication overuse treated in clinical and observational studies. Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Across studies, onabotulinumtoxinA was well tolerated; adverse events tended to be mild or moderate in severity and to decline over subsequent treatment cycles.
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
Nemes, Sára , Logan, Paige E. , Manchella, Mohit K. , Mundada, Nidhi S. , Joie, Renaud La , Polsinelli, Angelina J. , Hammers, Dustin B. , Foroud, Tatiana M., Eloyan, Ani , Dorsant‐Ardón, Valérie , Taurone, Alexander, Thangarajah, Maryanne, Dage, Jeffrey L. , Aisen, Paul , Grinberg, Lea T. , Kramer, Joel H. , Kukull, Walter A. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Touroutoglou, Alexandra , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Rabinovici, Gil D. , Carrillo, María C. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Koeppe, Robert A. , Nudelman, Kelly , Iaccarino, Leonardo , Jack, Clifford R. , Murray, Melissa E. , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Womack, Kyle , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | July 27, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13403 | PMID 37496307 Get It

AbstractINTRODUCTIONWe used sex and apolipoprotein E ε4 (APOE ε4) carrier status as predictors of pathologic burden in early‐onset Alzheimer's disease (EOAD).METHODSWe included baseline data from 77 cognitively normal (CN), 230 EOAD, and 70 EO non‐Alzheimer's disease (EOnonAD) participants from the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS). We stratified each diagnostic group by males and females, then further subdivided each sex by APOE ε4 carrier status and compared imaging biomarkers in each stratification. Voxel‐wise multiple linear regressions yielded statistical brain maps of gray matter density, amyloid, and tau PET burden.RESULTSEOAD females had greater amyloid and tau PET burdens than males. EOAD female APOE ε4 non‐carriers had greater amyloid PET burdens and greater gray matter atrophy than female ε4 carriers. EOnonAD female ε4 non‐carriers also had greater gray matter atrophy than female ε4 carriers.DISCUSSIONThe effects of sex and APOE ε4 must be considered when studying these populations.HIGHLIGHTS Novel analysis examining the effects of biological sex and apolipoprotein E ε4 (APOE ε4) carrier status on neuroimaging biomarkers among early‐onset Alzheimer's disease (EOAD), early‐onset non‐AD (EOnonAD), and cognitively normal (CN) participants. Female sex is associated with greater pathology burden in the EOAD cohort compared to male sex. The effect of APOE ε4 carrier status on pathology burden was the most impactful in females across all cohorts.
Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial
Gui, Hongsheng , Tang, W.H. Wilson , Francke, Stephan, Li, Jia , She, Ruicong , Bazeley, Peter , Pereira, Naveen L. , Adams, Kirkwood F., Williams, L. Keoki , Luzum, Jasmine A , Hernandez, Adrian , McNaughton, Candace D , Williams, L Keoki , Lanfear, David E , Tang, W H Wilson , Luzum, Jasmine A. , Connolly, Thomas M., Hernandez, Adrian F.

Mayo Clinic

Circulation: Heart Failure | July 26, 2023 | Volume: 16 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.122.010438 | PMID 37725680 Get It

BACKGROUND: Heart failure remains a global health burden, and patients hospitalized are particularly at risk, but genetic associates for subsequent death or rehospitalization are still lacking. METHODS: The genetic substudy of the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) was used to perform genome-wide association study and transethnic meta-analysis. The overall trial included the patients of self-reported European ancestry (n=2173) and African ancestry (n=507). The end point was death or heart failure rehospitalization within 180 days. Cox models adjusted for 11 a priori predictors of rehospitalization and 5 genetic principal components were used to test the association between single-nucleotide polymorphisms and outcome. Summary statistics from the 2 populations were combined via meta-analysis with the significance threshold considered P <5×10 − 8 . RESULTS: Common variants (rs2342882 and rs35850039 in complete linkage disequilibrium) located in FGD5 were significantly associated with the primary outcome in both ancestry groups (European Americans: hazard ratio [HR], 1.38; P =2.42×10 −6 ; African ancestry: HR, 1.51; P =4.43×10 − 3 ; HR in meta-analysis, 1.41; P =4.25×10 −8 ). FGD5 encodes a regulator of VEGF (vascular endothelial growth factor)-mediated angiogenesis, and in silico investigation revealed several previous genome-wide association study hits in this gene, among which rs748431 was associated with our outcome (HR, 1.20; meta P <0.01). Sensitivity analysis proved FGD5 common variants survival association did not appear to operate via coronary artery disease or nesiritide treatment ( P >0.05); and the signal was still significant when changing the censoring time from 180 to 30 days (HR, 1.39; P =1.59×10 −5 ). CONCLUSIONS: In this multiethnic genome-wide association study of ASCEND-HF, single-nucleotide polymorphisms in FGD5 were associated with increased risk of death or rehospitalization. Additional investigation is required to examine biological mechanisms and whether FGD5 could be a therapeutic target. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00475852.
White matter hyperintensities are higher among early‐onset Alzheimer's disease participants than their cognitively normal and early‐onset nonAD peers: Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Eloyan, Ani , Thangarajah, Maryanne, An, Na , Borowski, Bret, Reddy, Ashritha L., Aisen, Paul , Dage, Jeffrey L. , Ghetti, Bernardino , Griffin, Percy , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel H. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Touroutoglou, Alexandra , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Gao, Sujuan , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Dickerson, Brad C., Vemuri, Prashanthi , Borowski, Bret J, Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Ghetti, Bernardino F , Wingo, Thomas S , Dage, Jeffrey L , An, Na, Reddy, Ashritha L., Foroud, Tatiana , Hammers, Dustin B , Iaccarino, Leonardo , Jack, Clifford R. , Kirby, Kala, Koeppe, Robert A. , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Womack, Kyle , Beckett, Laurel

Mayo Clinic

Alzheimer's & Dementia | July 25, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13402 | PMID 37491599 Get It

Abstract INTRODUCTION We compared white matter hyperintensities (WMHs) in early‐onset Alzheimer's disease (EOAD) with cognitively normal (CN) and early‐onset amyloid‐negative cognitively impaired (EOnonAD) groups in the Longitudinal Early‐Onset Alzheimer's Disease Study. METHODS We investigated the role of increased WMH in cognition and amyloid and tau burden. We compared WMH burden of 205 EOAD, 68 EOnonAD, and 89 CN participants in lobar regions using t ‐tests and analyses of covariance. Linear regression analyses were used to investigate the association between WMH and cognitive impairment and that between amyloid and tau burden. RESULTS EOAD showed greater WMHs compared with CN and EOnonAD participants across all regions with no significant differences between CN and EOnonAD groups. Greater WMHs were associated with worse cognition. Tau burden was positively associated with WMH burden in the EOAD group. DISCUSSION EOAD consistently showed higher WMH volumes. Overall, greater WMHs were associated with worse cognition and higher tau burden in EOAD. Highlights This study represents a comprehensive characterization of WMHs in sporadic EOAD. WMH volumes are associated with tau burden from positron emission tomography (PET) in EOAD, suggesting WMHs are correlated with increasing burden of AD. Greater WMH volumes are associated with worse performance on global cognitive tests. EOAD participants have higher WMH volumes compared with CN and early‐onset amyloid‐negative cognitively impaired (EOnonAD) groups across all brain regions.